Feasibility
Studies currently in Feasibility
Embedded Files
Last content update - 15th December 2023
Please contact the: R&D Coordinators for more information
All Specialties
No trials currently in feasibility
No trials currently in feasibility
Specialty:
CPMS No:
Estimated Opening:
Description:
BLADDER
No trials currently in feasibility
No trials currently in feasibility
BREAST
HER2-RADiCAL
Specialty: Breast
CPMS No:
Estimated Opening: To be announced
Description: The HER2-RADiCAL study is for patients with HER2-positive breast cancer who: -started their course of drug treatment (chemotherapy + trastuzumab + pertuzumab) before surgery; -have had breast surgery; -and have been found to have the best possible response to treatment (a “pathological complete response” or “pCR”).
COLORECTAL
FOxTROT platform
Specialty: Colorectal
CPMS No: 49772
Estimated Opening: To be announced
Description: The FOxTROT platform is a rolling programme of molecularly stratified,randomised phase II/III,multi-centre,international,open-label studies.
GYNAE
No trials currently in feasibility
No trials currently in feasibility
Head & Neck
No trials currently in feasibility
No trials currently in feasibility
Multiple Specialties
No trials currently in feasibility
No trials currently in feasibility
PROSTATE
ELIPSE
ELIPSE
Speciality: Prostate
CPMS No: 63289
Estimated Opening: To be announced
Description: A randomised controlled trial comparing the clinical and cost-effectiveness of lymph node removal in patients undergoing
curative surgery for localised high-risk Prostate Cancer. (ELIPSE)
MEVPRO-1
MEVPRO-1
Speciality: Prostate
CPMS No:
Estimated Opening: To be announced
Description: PHASE 3, RANDOMIZED, OPEN-LABEL STUDY OF PF-06821497 (MEVROMETOSTAT) IN COMBINATION WITH ENZALUTAMIDE COMPARED WITH ENZALUTAMIDE OR DOCETAXEL IN PARTICIPANTS WITH METASTATIC CASTRATION RESISTANT PROSTATE CANCER PREVIOUSLY TREATED WITH ABIRATERONE ACETATE (MEVPRO-1)
MEVPRO-2
MEVPRO-2
Speciality: Prostate
CPMS No:
Estimated Opening: To be announced
Description: A PHASE 3, RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED STUDY OF PF-06821497 (MEVROMETOSTAT) WITH ENZALUTAMIDE IN METASTATIC CASTRATION RESISTANT PROSTATE CANCER (MEVPRO-2)
RADIOTHERAPY
No trials currently in feasibility
No trials currently in feasibility
RENAL
No trials currently in feasibility
No trials currently in feasibility
SKIN
SCC-After
SCC-After
speciality: SKIN
CPMS No:
Estimated Opening: To be announced
Description: Adjuvant Radiotherapy in Patients with High-risk Primary Cutaneous Squamous Cell Carcinoma AFTER surgery (SCC-AFTER): An Open Label, Multicentre, Two-arm Phase III Randomised trial.
LUNG
REFINE-Lung
REFINE-Lung
speciality: Lung
CPMS No:
Estimated Opening: To be announced
Description: Reduced Frequency pembrolizumab immunotherapy for first line treatment of patients with advanced non-small cell lung cancer (NSCLC) utilising a novel multi-arm frequency-response optimisation design.
Report abuse